DLBCL
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
From the Journals
First-line CAR T-cell therapy could help cure some lymphomas
Axi-cel is already approved for some forms of relapsed/refractory lymphoma, and a new phase 2 study hints that it has potential as a frontline...
Feature
Repurposed drug could revolutionize stem cell transplantation
Abatacept to prevent for acute graft-versus-host disease is a game changer for patients receiving hematopoietic stem cell transplants who lack...
Latest News
EMA gives green light to new CAR T-cell therapy
The committee also recommended approval of a biosimilar product for pegfilgrastim.
Latest News
Yescarta label updated: Prophylactic steroids to prevent CRS
New Yescarta labeling advises clinicians to consider using corticosteroids to ward off cytokine release syndrome.
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
Feature
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
From the Journals
In some lymphomas, ibrutinib yields “almost unheard-of” survival rates
Adding ibrutinib to standard chemotherapy improves DLBCL survival in younger patients, especially among certain genetic subtypes.
From the Journals
Easing access to DLBCL treatments: Patient study reveals racial differences
Collaborative follow-up models could improve access to cellular therapies, but more customized strategies are also needed.